Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma

BMC Cancer

Liqun Gu¹  Chao Zhu²  Mianfeng Yao²  Jiang Li²  Changyun Fang²  Zelong Liu³ 

[1] Department of Pediatric Stomatology, Xiangya Stomatological Hospital, Central South University, Changsha, China;Department of Stomatology, Xiangya Hospital, Central South University, Changsha, China;Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;

关键词: Vascular endothelial growth factor;    Immune microenvironment;    Head and neck squamous cell carcinoma;    Immunotherapy;   

DOI  :  10.1186/s12885-021-08547-4

来源: Springer

【 摘 要 】

BackgroundImmunotherapy is a crucial therapeutic approach in oncology. However, most patients with head and neck squamous cell carcinoma (HNSCC) do not derive benefit from immunotherapy. Vascular endothelial growth factor (VEGF)/VEGF Receptor 2 (VEGFR2) signaling pathway is one of the most important pathways regulating angiogenesis in tumor. The combination of immunotherapy and anti-angiogenic therapy is considered to improve efficacy of immunotherapy. The correlation between VEGF signaling pathway and tumor immune microenvironment in HNSCC patients is unclear.MethodsWe utilized RNA sequencing and clinical data of HNSCC patients from the TCGA database to study the correlation between VEGF signaling pathway and tumor immune microenvironment, on aspect of immune cell infiltration, immune-related gene expression profiling and immune-related biological pathways.ResultsWe observed that VEGF signaling pathway is positively correlated with immune cell infiltration, immune-related gene expression profiles, and the prognosis of HNSCC patients. The functional enrichment analysis of differentially expressed genes between different VEGF score subtypes detected multiple immune-related biological processes.ConclusionOur findings suggested that combining anti-VEGF signaling pathway agents with immunotherapy, such as immune checkpoint inhibitors (ICI) therapy, may exhibit encouraging benefits in HNSCC.

【 授权许可】

CC BY